MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$14,520,826
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from the issuance of co...
Proceeds from the issuance of co...
Maturities of marketable securit...
Others
Negative Cash Flow Breakdown
Net loss
Purchase of marketable securitie...
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-6,571,656
-7,964,158
-8,087,290
-7,726,639
Accretion of discount on marketable securities, net
19,139
70,104
146,058
221,525
Stock-based compensation expense
362,275
349,196
298,735
291,717
Prepaid expenses and other assets
-961,623
428,336
-418,967
-278,355
Deferred offering costs
0
-
41,250
105,977
Accounts payable
-1,532,371
765,364
94,899
-434,813
Accrued expenses and other current liabilities
-119,157
-1,097,293
-48,096
454,084
Grant receivable
0
-426,993
-934,394
-999,588
Net cash used in operating activities
-6,918,425
-8,018,338
-6,575,699
-6,465,210
Purchase of marketable securities
2,473,912
989,180
4,626,232
3,918,103
Maturities of marketable securities
5,000,000
8,700,000
10,000,000
11,500,000
Net cash provided by investing activities
2,526,088
7,710,820
5,373,768
7,581,897
Proceeds from the exercise of stock options
0
13,800
-
-
Proceeds from the issuance of common stock, net of issuance costs - 2026 private placement-Private Placement
9,685,402
-
-
-
Proceeds from sale of common stock, prefunded warrants and common stock warrants
-
-
0
0
Proceeds from the issuance of common stock, net of issuance costs - 2026 private placement-Registered Direct Offering
9,227,761
-
-
-
Proceeds from the issuance of common stock, net of issuance costs - 2026 private placement-Open Market Sales Agreement
0
-
0
0
Net cash provided by financing activities
18,913,163
13,800
0
0
Net (decrease) increase in cash and cash equivalents
14,520,826
-293,718
-1,201,931
1,116,687
Cash and cash equivalents at beginning of period
7,941,751
8,235,469
9,437,400
8,999,496
Cash and cash equivalents at end of period
22,462,577
7,941,751
8,235,469
9,437,400
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from the
issuance of common stock,...
$9,685,402
Proceeds from the
issuance of common stock,...
$9,227,761
Maturities of marketable
securities
$5,000,000
(-77.27%↓ Y/Y)
Net cash provided by
financing activities
$18,913,163
(312.17%↑ Y/Y)
Net cash provided by
investing activities
$2,526,088
(-50.87%↓ Y/Y)
Canceled cashflow
$2,473,912
Net (decrease)
increase in cash and cash...
$14,520,826
(2239.24%↑ Y/Y)
Canceled cashflow
$6,918,425
Prepaid expenses and
other assets
-$961,623
(-1730.78%↓ Y/Y)
Stock-based compensation
expense
$362,275
(-57.79%↓ Y/Y)
Purchase of marketable
securities
$2,473,912
(-85.33%↓ Y/Y)
Net cash used in
operating activities
-$6,918,425
(33.53%↑ Y/Y)
Canceled cashflow
$1,323,898
Net loss
-$6,571,656
(41.07%↑ Y/Y)
Accounts payable
-$1,532,371
(-662.15%↓ Y/Y)
Accrued expenses and
other current...
-$119,157
(-127.83%↓ Y/Y)
Accretion of discount on
marketable securities, net
$19,139
(-96.07%↓ Y/Y)
Buy us a coffee
CervoMed Inc. (CRVO)
CervoMed Inc. (CRVO)